Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.46 |
| ▸ | PTPRC | P08575 | 2/20 | 0.46 |
| ▸ | PTPRF | P10586 | 1/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | BACE1 | P56817 | 5/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.38 |
| ▸ | EDNRB | P24530 | 2/20 | 0.36 |
| ▸ | EDNRA | P25101 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5549225 | 0.79 | PTPN1 (0.38) | PTPN1PTPRCPTPRFCDC25BBACE1 | |
| SCHEMBL28806317 | 0.69 | ALDH1A1 (0.37) | PTPN1PTPRCPTPRFCDC25BBACE1 | |
| SCHEMBL25834603 | 0.68 | BACE1 (0.42) | PTPN1PTPRCPTPRFCDC25BBACE1 | |
| SCHEMBL15906510 | 0.68 | CYP2D6 (0.47) | CDC25BHDAC4HDAC8HDAC6MAOA | |
| SCHEMBL5436457 | 0.68 | EDNRB (0.55) | PTPRCCDC25BMAOAMAOBEDNRB | |
| SCHEMBL29376368 | 0.66 | MAOA (0.52) | HDAC4HDAC8HDAC6MAOAMAOB | |
| SCHEMBL216862 | 0.66 | MAOA (0.52) | HDAC4HDAC8HDAC6MAOAMAOB | |
| SCHEMBL29884836 | 0.66 | MAOA (0.52) | HDAC4HDAC8HDAC6MAOAMAOB | |
| SCHEMBL30433091 | 0.66 | PTPN1 (0.76) | PTPN1PTPRCPTPRFCDC25BBACE1 | |
| SCHEMBL5139479 | 0.66 | PTPN1 (0.76) | PTPN1PTPRCPTPRFCDC25BBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200147086-A1 | INHIBITORS OF NUCLEOTIDYLTRANSFERASE SUPERFAMILY ENZYMES AS ANTIBIOTICS | SAINT LOUIS UNIVERSITY (US) | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200147086-A1 | INHIBITORS OF NUCLEOTIDYLTRANSFERASE SUPERFAMILY ENZYMES AS ANTIBIOTICS | DNTT, APRT, RNGTT | PTPN1 2768/4885PTPRC 3505/4885PTPRF 2295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.